Ge Fu

809 citations
11 papers · 660 indexed · h-index 10

Impact in

  • Pharmacology top 10%
    • Pharmacological Effects of Natural Compounds
    • Toxin Mechanisms and Immunotoxins
    • interferon and immune responses
    • Immune Response and Inflammation

Papers in

    • Toxin Mechanisms and Immunotoxins 3
    • Immune Response and Inflammation 2
    • interferon and immune responses 1

Ge Fu

11 papers receiving 657 citations

Peers

Ge Fu
Comparison fields: 5 of 78
  • Pharmacology 70
  • Immunology 163
  • Molecular Biology 371
  • Toxicology 18
  • Epidemiology 162
Replace Haijun Li with:
Haijun Li China
Vijayakumar Gosu South Korea
Yun Xing China
Su Ui Lee South Korea
Saikat Chakrabarti India
Shengyuan Zhang China
Pinyi Lu United States
Zahra Khan South Korea
Amy Fung United States
Maria Viskaduraki United Kingdom
Ge Fu relative to Haijun Li China Haijun Li's profile →
Citations per field
00.5×
Haijun Li · 1×
Citations per year

Countries citing papers authored by Ge Fu

Since Specialization
Citations

This map shows the geographic impact of Ge Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ge Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ge Fu more than expected).

Fields of papers citing papers by Ge Fu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ge Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ge Fu. The network helps show where Ge Fu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ge Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ge Fu Line = papers co-authored together Ge Fu links everyone, so they are left out of the graph.

All Works

11 of 11 papers shown
#Work
1 201870
2 201746
3 201745
4 201716
5 2017117
6 2016133
7 201630
8 201559
9 2014131
10 20144
11 20129

About Ge Fu

Ge Fu is a scholar working on Immunology, Physiology, Nephrology, Cell Biology and Analytical Chemistry, having authored 11 papers that have together received 660 indexed citations. Recurring topics across this work include Toxin Mechanisms and Immunotoxins (3 papers), Influenza Virus Research Studies (2 papers), Immune Response and Inflammation (2 papers), Glycosylation and Glycoproteins Research (1 paper), SARS-CoV-2 and COVID-19 Research (1 paper), Respiratory viral infections research (1 paper), interferon and immune responses (1 paper) and Endoplasmic Reticulum Stress and Disease (1 paper). The work is most often cited by research in Pharmacology (70 citations), Immunology (163 citations), Molecular Biology (371 citations), Toxicology (18 citations) and Epidemiology (162 citations). Ge Fu has collaborated with scholars based in China, United States and Macao. Frequent co-authors include Demin Zhou, Longlong Si, Sulong Xiao, Lihe Zhang, Yiming Wu, Ke‐Wu Zeng, Xiaomin Song, Peng‐Fei Tu, Zhenyu Tian and Ziwei Zhang. Their work appears in journals such as Biomaterials, Journal of the American Society of Nephrology, Science, EBioMedicine and Oncotarget.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026